Madison, WI, October 12, 2020 — Elephas Biosciences Corporation(Elephas), a live tumor imaging company developing novel cancer diagnostic solutions, announced today Ann Leonard has joined the company as Director of Quality.
Leonard is an accomplished expert with broad experience managing quality, regulatory, and business requirements for the medical device, pharmaceutical, and biotechnology industries. Leonard will be responsible for developing, managing, and improving quality management system core processes compliant with ISO 9001, ISO 13485, and FDA QSR for the company.
"Investing in leadership to build a quality department at this early stage is critically important,” said Maneesh Arora, founder and CEO of Elephas. "Ann’s impressive track record, paired with her experience across all areas of quality and compliance, will be important drivers of our platform development in the coming years”.
An ASQ Certified Manager of Quality & Organizational Excellence, Leonard started her career at Promega before joining Mueller Sports Medicine as a Director of Quality Systems & Material Quality. Most recently, she served as a Global Quality Manager at Thermo Fisher Scientific.
"Elephas’ dedicated team, and mission develop innovative solutions for cancer patients is why I am so excited to join,” said Leonard. “And in order to make the extraordinary impact that this platform is capable of, it’s key that all quality, compliance, and certifications are carefully planned from the beginning”
Leonard earned her bachelor’s degree in animal science from Iowa State University, an MBA in quality management from Upper Iowa University, and a graduate certificate in biopharmaceutical international regulatory affairs from Northeastern University.
About Elephas
Cancer is a leading cause of death worldwide, with the number of patients projected to triple by 2060. Despite a significant increase in the number of available immunotherapies, only 1 in 5 patients receiving immunotherapy obtain a response and many who may respond are not eligible for therapy due to lack of accurate predictive biomarkers. With the mission to tackle the massive oncology dilemma, Elephas has developed an ex-vivo platform to assess how live patient biopsies respond to immunotherapies. By preserving the native tumor microenvironment from a live core needle biopsy and using a novel method to address tumor heterogeneity, the Elephas Live platform enables a real-time characterization of immune response. To learn more, visit us at www.elephas.com or follow us on LinkedIn.
Contact
John Fitzpatrick
marketing@elephas.com
